Patent ID: 7696165

Claim:
A method of treating a mammal with hepatitis C comprising: administering to the mammal a therapeutically effective amount of a compound having the following formula: wherein: X is OH or OAc; R 0 is H, CH 2 OH, or CH 2 OR 2 ; R 1 is selected from the group consisting of: hydrogen; halogen; C 2 -C 6 saturated or unsaturated, straight or branched carbon chain; C 2 -C 6 saturated or unsaturated, straight or branched carbon chain containing substitution or substitutions selected from the group consisting of deuterium, halogen, nitrogen, sulfur, and silicon atom or atoms; C 2 -C 6 saturated or unsaturated, straight or branched carbon chain containing a function group or function groups selected from the group consisting of alcohol, ether, aldehyde, ketone, carboxylic ester, and amide; C 2 -C 4 saturated or unsaturated, straight or branched carbon chain containing an aryl or a heteroaryl; C 3 -C 6 -substituted and unsubstituted cycloalkyl; substituted and unsubstituted aryl; substituted and unsubstituted heteroaryl; —CH 2 OH; —CHO; —CH═N—OR 3 ; and —CH═N—NR 3 R 4 ; R 2 is selected from the group consisting of: alkanoyl; alkenoyl; alkynoyl; aryloyl; arylalkanoyl; alkylaminocarbonyl; arylaminocarbonyl; arylalkylaminocarbonyl; alkyloxycarbonyl; aryloxycarbonyl; and arylalkyloxycarbonyl; R 3 or R 4 are the same or different and independently selected from the group consisting of: hydrogen; C 1 -C 6 saturated straight or branched carbon chain; C 3 -C 6 unsaturated straight or branched carbon chain; C 3 -C 6 -substituted and unsubstituted cycloalkyl; C 1 -C 4 carbon chain containing an aryl or heteroaryl; substituted and unsubstituted aryl; substituted and unsubstituted heteroaryl; alkanoyl; alkenoyl; alkynoyl; aryloyl; arylalkanoyl; alkylaminocarbonyl; arylaminocarbonyl; arylalkylaminocarbonyl; alkyloxycarbonyl; aryloxycarbonyl; and arylalkyloxycarbonyl; and R 3 together with R 4 results in the formation of a cyclic moiety of C 2 -C 6 optionally containing heteroatom or heteroatoms, or a pharmaceutically acceptable salt thereof, under conditions effective to treat hepatitis C.